BlackRock Inc. increased its holdings in ICU Medical, Incorporated (NASDAQ:ICUI) by 0.8% during the 1st quarter, HoldingsChannel reports. The fund owned 1,485,971 shares of the medical instruments supplier’s stock after acquiring an additional 12,345 shares during the quarter. BlackRock Inc. owned about 0.07% of ICU Medical worth $355,639,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in ICUI. Smith Moore & CO. bought a new stake in shares of ICU Medical in the fourth quarter valued at about $254,000. Amalgamated Bank lifted its stake in ICU Medical by 59.6% during the fourth quarter. Amalgamated Bank now owns 3,660 shares of the medical instruments supplier’s stock worth $840,000 after purchasing an additional 1,367 shares during the period. Rhumbline Advisers lifted its stake in ICU Medical by 1.3% during the first quarter. Rhumbline Advisers now owns 45,901 shares of the medical instruments supplier’s stock worth $10,985,000 after purchasing an additional 575 shares during the period. Texas Permanent School Fund lifted its stake in ICU Medical by 3.8% during the first quarter. Texas Permanent School Fund now owns 11,274 shares of the medical instruments supplier’s stock worth $2,698,000 after purchasing an additional 414 shares during the period. Finally, Raymond James Trust N.A. lifted its stake in ICU Medical by 47.4% during the first quarter. Raymond James Trust N.A. now owns 1,480 shares of the medical instruments supplier’s stock worth $354,000 after purchasing an additional 476 shares during the period. Institutional investors and hedge funds own 90.05% of the company’s stock.
NASDAQ:ICUI opened at $237.97 on Wednesday. ICU Medical, Incorporated has a 1 year low of $210.94 and a 1 year high of $321.70. The company has a market capitalization of $4.75 billion, a PE ratio of 30.87 and a beta of 0.72.
ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.39. ICU Medical had a net margin of 4.04% and a return on equity of 13.70%. The company had revenue of $330.93 million during the quarter, compared to analysts’ expectations of $318.97 million. During the same quarter in the previous year, the company posted $2.26 earnings per share. ICU Medical’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, sell-side analysts forecast that ICU Medical, Incorporated will post 8.55 EPS for the current fiscal year.
ICUI has been the subject of a number of analyst reports. Raymond James cut their price target on shares of ICU Medical from $315.00 to $300.00 and set a “strong-buy” rating for the company in a research note on Friday, March 1st. BidaskClub cut shares of ICU Medical from a “hold” rating to a “sell” rating in a research note on Friday, April 5th. TheStreet cut shares of ICU Medical from a “b-” rating to a “c+” rating in a research note on Tuesday, March 19th. Finally, Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $262.00 price target for the company in a research note on Thursday, March 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $281.00.
In other news, Director Robert S. Swinney sold 1,464 shares of ICU Medical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $234.65, for a total value of $343,527.60. Following the completion of the transaction, the director now owns 16,576 shares in the company, valued at $3,889,558.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert S. Swinney sold 229 shares of ICU Medical stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $231.43, for a total transaction of $52,997.47. Following the completion of the transaction, the director now owns 18,076 shares of the company’s stock, valued at approximately $4,183,328.68. The disclosure for this sale can be found here. Insiders sold 14,385 shares of company stock valued at $3,315,134 in the last quarter. 11.40% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/06/12/icu-medical-incorporated-nasdaqicui-position-lifted-by-blackrock-inc.html.
ICU Medical Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Featured Story: What can cause a stock to outperform?
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Incorporated (NASDAQ:ICUI).
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.